1. Home
  2. LGND vs KEN Comparison

LGND vs KEN Comparison

Compare LGND & KEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • KEN
  • Stock Information
  • Founded
  • LGND 1987
  • KEN 2014
  • Country
  • LGND United States
  • KEN Singapore
  • Employees
  • LGND N/A
  • KEN N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • KEN Electric Utilities: Central
  • Sector
  • LGND Health Care
  • KEN Utilities
  • Exchange
  • LGND Nasdaq
  • KEN Nasdaq
  • Market Cap
  • LGND 2.0B
  • KEN 2.2B
  • IPO Year
  • LGND 1992
  • KEN N/A
  • Fundamental
  • Price
  • LGND $124.30
  • KEN $44.70
  • Analyst Decision
  • LGND Strong Buy
  • KEN
  • Analyst Count
  • LGND 8
  • KEN 0
  • Target Price
  • LGND $144.71
  • KEN N/A
  • AVG Volume (30 Days)
  • LGND 139.7K
  • KEN 23.1K
  • Earning Date
  • LGND 08-05-2025
  • KEN 09-08-2025
  • Dividend Yield
  • LGND N/A
  • KEN 10.69%
  • EPS Growth
  • LGND N/A
  • KEN N/A
  • EPS
  • LGND N/A
  • KEN 11.35
  • Revenue
  • LGND $181,488,000.00
  • KEN $760,304,000.00
  • Revenue This Year
  • LGND $18.41
  • KEN N/A
  • Revenue Next Year
  • LGND $18.87
  • KEN N/A
  • P/E Ratio
  • LGND N/A
  • KEN $3.90
  • Revenue Growth
  • LGND 53.40
  • KEN 5.78
  • 52 Week Low
  • LGND $81.74
  • KEN $23.31
  • 52 Week High
  • LGND $129.90
  • KEN $46.03
  • Technical
  • Relative Strength Index (RSI)
  • LGND 64.68
  • KEN 74.43
  • Support Level
  • LGND $120.68
  • KEN $44.05
  • Resistance Level
  • LGND $127.07
  • KEN $46.03
  • Average True Range (ATR)
  • LGND 3.76
  • KEN 0.80
  • MACD
  • LGND 0.86
  • KEN 0.14
  • Stochastic Oscillator
  • LGND 81.95
  • KEN 81.40

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About KEN Kenon Holdings Ltd.

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.

Share on Social Networks: